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OBJECTIVES: Epithelial gaps resulting from intestinal cell extrusions can be visualized with confocal laser endomicroscopy
(CLE) during colonoscopy and increased in normal-appearing terminal ileum of inﬂammatory bowel disease (IBD) patients. Cell-
sheddingeventsonCLEwerefoundtobepredictiveofdiseaserelapse.Theaimofthisstudywastoassesstheprognosticvalue
of epithelial gap densities for major clinical events (hospitalization or surgery) in follow-up.
METHODS: We prospectively followed IBD patients undergoing colonoscopy with probe-based CLE (pCLE) for clinical events
including symptom ﬂares, medication changes, hospitalization, or surgery. Survival analysis methods were used to compare
event times for the composite outcome of hospitalization or surgery using log-rank tests and Cox proportional hazards models.
We also examined the relationship of gap density with IBD ﬂares, need for anti-tumor necrosis factor therapy, disease duration,
gender and endoscopic disease severity, and location.
RESULTS: A total of 21 Crohn’s disease and 20 ulcerative colitis patients with a median follow-up of 14 (11–31) months
were studied. Patients with elevated gap density were at signiﬁcantly higher risk for hospitalization or surgery (log-rank
test P¼0.02). Gap density was a signiﬁcant predictor for risk of major events, with a hazard ratio of 1.10 (95% conﬁdence
interval¼1.01, 1.20) associated with each increase of 1% in gap density. Gap density was also correlated with IBD disease
duration (Spearman’s correlation coefﬁcient rho¼0.44, P¼0.004), and was higher in male patients (9.0 vs. 3.6 gaps per 100
cells, P¼0.038).
CONCLUSIONS: Increased epithelial gaps in the small intestine as determined by pCLE are a predictor for future hospitalization
or surgery in IBD patients.
Clinical and Translational Gastroenterology (2012) 3, e19; doi:10.1038/ctg.2012.13; published online 26 July 2012
Subject Category: Inﬂammatory bowel disease
INTRODUCTION
Altered intestinal permeability has been implicated in the
pathogenesis of inﬂammatory bowel disease (IBD).
1,2
Increased gut permeability has been well demonstrated
in patients with Crohn’s disease (CD) and their ﬁrst-degree
relatives,
3,4 and appears to predict impending disease
relapse.
5 Changes in tight-junction protein expression in
active CD patients
6 and correlation of colitis severity with
alterations of intestinal permeability in rodent models
7,8
further support the notion that barrier dysfunction has an
important role in the development of IBD. The barrier function
oftheintestinal epithelium ismaintained byepithelial cellsand
tight junctions in between cells, allowing absorption of
nutrients while preventing undesirable solutes, microbes,
and antigens from entering the body.
9,10 Stem cells in the
base of crypts produce new epithelial cells that mature and
migrate to the top of the intestinal villi, where they are
eventually shed.
11 In rodent studies, extrusion of an intestinal
epithelial cell leaves a gap or discontinuity in the epithelium
that may take up to 12min to resolve, and may potentially
compromise the barrier function.
12 Increased cell shedding
induced by tumor necrosis factor (TNF) has been shown to
result in barrier dysfunction in the intestine.
13 In patients,
these epithelial gaps can be observed using confocal laser
endomicroscopy (CLE) with administration of ﬂuorescein.
13,14
CLE is a novelendoscopic imaging modality investigated for a
number of indications in IBD, including classiﬁcation of
mucosal inﬂammation,
15 detection of intramucosal neopla-
sia,
16,17 and identiﬁcation of epithelial gaps in the small
intestineaftercellextrusion.
13,14 Wehavepreviouslyfoundan
increased density of epithelial gaps in the small intestine of
IBD patients.
18 Recently, epithelial gaps and cell-shedding
events observed using CLE were shown to be predictive of
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meters, and endoscopic severity in CD patients.
21,22 A
number of clinical and laboratory parameters were previously
reported to be associated with poor clinical outcome: young





23 perinuclear anti-neutrophil cytoplasmic
antibodies (pANCA)/anti-Saccharomyces cerevisiae anti-
bodies (ASCA) titer,
26,27 C-reactive protein (CRP),
28,29 panco-
litis,
30,31 presence of primary sclerosing cholangitis,
25,32 and
granuloma.
33 Endoscopic ﬁnding of mucosal healing,
32
particularly after administration of anti-TNF therapy, is pre-
dictive of favorable clinical outcome,
34,35 whereas lack of
mucosal healing on therapy is associated with a more aggres-
sive disease course.
36 Endoscopic indices are increasingly
used to determine the efﬁcacy of various therapeutic agents
for IBD, with mucosal healing considered to be important in
predicting disease outcome, including colectomy in ulcerative
colitis (UC) and surgery and hospitalization in CD. We
hypothesizethatincreasedintestinalcellextrusion(measured
as an increased epithelial gap density) is a surrogate marker
for barrier dysfunction in IBD, and thus may have predictive
value for clinical disease course and outcomes. In our
previous study,
18 a retrospective review of disease course
before colonoscopy with probe-based CLE (pCLE) revealed a
possible relationship between the epithelial gap density and
major clinical events (hospitalization or surgery) in the year
preceding pCLE.
The aim of this study was to assess the predictive value of
epithelial gaps for major clinical events (hospitalization or
surgery) in IBD patients undergoing colonoscopy. We also
examinedtherelationshipofepithelialgapdensitywithrespect
to disease duration, gender, number of ﬂares in the follow-up
period, and endoscopic disease severity and location.
METHODS
This was a prospective, double-blinded, observational cohort
follow-up study of IBD patients undergoing pCLE of the
terminal ileum during standard-of-care colonoscopy. Patient
enrollment was from March 2009 to November 2010, with the
follow-up period ending in October 2011. We recruited more
UC patients in addition to patients from our study on epithelial
gap density in IBD
18 and a pilot study in CD
14 based on our
sample size calculation for follow-up. The study was
registered at ClinicalTrial.Gov (NCT00988273). The study
protocol was reviewed and approved by the Human Ethics
ResearchReview Board at the University of Alberta, Edmon-
ton, Alberta, Canada. The study group consisted of patients
with known or newly diagnosed IBD undergoing colonoscopy
for clinical indications (evaluation of symptoms or cancer
surveillance). The inclusion criteria for the study were age
over 18 years and the ability to give informed consent.
Exclusion criteria included having known allergies to ﬂuor-
escein or shellﬁsh, impaired renal function (serum creatinine
over 1.5mg/dl) or being pregnant or nursing patients. All
patients gave written informed consent to participate in the
study. The disease status of patients undergoing colonosco-
pies was classiﬁed as active disease (evaluation of symp-
toms) or inactive disease (asymptomatic patients undergoing
cancer surveillance). Patient demographics, history, physical
examination ﬁndings, and endoscopic ﬁndings were recorded
in a database.
All patients successfully underwent colonoscopy with
intubation of the terminal ileum, at which time 5ml of 10%
ﬂuorescein solution was administered intravenously. Con-
focal images of the terminal ileum were obtained with the
ultra-high-deﬁnition pCLE probe (UHD Coloﬂex, Mauna Kea
Technologies, Paris, France) following a previously reported
protocol.
18 Frame-by-frame confocal images of normal-
appearing terminal ileum at about 10cm proximal to the
ileocecal valve were collected and digitally stored foranalysis.
pCLE imaging was limited to areas of endoscopically normal
mucosa in the terminal ileum. Review and analysis of pCLE
images were conducted in a post-hoc manner as previously
described.
18 In brief, pCLE images were blindly examined by
two reviewers for the selection of adequately imaged villi,
deﬁnedasvilli withatleast75%surfaceareavisualizedonthe
pCLE image, with at least three different consecutive views of
the villi seen. Epithelial cells and gaps were manually counted
in the villi and the highest frequency of epithelial gaps for any
individual patient was used to determine the gap density
(range: 3–10 villi evaluated per patient). The gap density
was calculated as the number of epithelial gaps per 100
epithelial cells counted in the adequately imaged villi.
Normal gap density was deﬁned as r6%, which was the
estimated 95th percentile of the control population from our
previous study.
18
Patient outcomes in the follow-up period after colonoscopy
with pCLE were tracked by a review of electronic medical
record systems for ﬂares, hospitalizations, surgeries, and
medicationchanges.TheprovinceofAlbertahassuccessfully
implemented a single, province-wide Electronic Health
Record (EHR)—Alberta Netcare. It is a database that
encompasses all inpatient visits, emergency room visits,
laboratory investigations, radiologic tests, endoscopic proce-
dures, surgeries, and hospitalizations within the province of
Alberta (http://www.albertanetcare.ca). Regardless of the
location of health-care delivery, the electronic medical record
can be accessed. The electronic medical record system also
tracks medication proﬁles and reﬁlls at most pharmacies
within the province of Alberta. The outpatient medical records
for all enrolled study patients are stored in the University of
Alberta Division of Gastroenterology electronic medical
database (Wolf Medical system), where all clinic visits are
recorded, including letters to and from referring primary-care
physicians. Flares in IBD patients were deﬁned as sympto-
matic changes requiring ofﬁce visits, including but not limited
to increased stool frequency, reduced stool consistency, or
presence of blood in stool. For Crohn’s patients, this
represented an increase in the Harvey–Bradshaw index of
42, and for UC patients, an increase of 2 in the partial Mayo
UC score. IBD-related surgeries in the follow-up period were
recorded for indications for surgery, type of surgery, and any
complications from the surgeries. For hospitalization, the
indications and number of hospitalizations were recorded. If a
patient had one hospitalization or surgery, it was counted as
one major event. Multiple admissions or surgeries for the
same patient were counted as one major event.
The primary-study end point was the cohort comparison of
the IBD-related hospitalization or surgery in patients with
Gaps Can Predict Aggressive IBD
Turcotte et al.
2
Clinical and Translational Gastroenterologynormal and elevated epithelial gap density as determined
by pCLE. Both clinicians and patients were blinded to the
result of pCLE and thus all treatment decisions regarding
patient management were made independently of pCLE
results during the follow-up. For secondary analyses, we
investigated the association between epithelial gap density
and durationof diseasetodetermineifexcesscell extrusion
increased with longer duration of disease. We also
examined whether epithelial gap density correlated with
the number of ﬂares in the follow-up period. The correlation
of gap density with endoscopic location and severity of
disease was also studied. Finally, we looked at epithelial
gap density and its relationship with gender, systemic
inﬂammatory markers (CRP levels), and the need for anti-
TNF therapy.
Statistical analysis
Sample size calculation. For the cutoff for abnormal gap
densities, we deﬁned gap density values 46% (the
estimated 95th percentile of the control population) to be
abnormal. On the basis of our previous study examining the
retrospective clinical course of patients undergoing pCLE
(23% vs. 60% hospitalization or surgery in the year
proceeding pCLE), we assumed median event-free survival
times, with respect to the primary outcome, of 32 and 9
months for patients with normal and elevated epithelial gap
density, respectively. To attain a statistical power of 0.80 with
an alpha of 0.05, and assuming an accrual period of 18
months with an additional 12 months of follow-up, a total of
38 patients were needed for this study, assuming equal
numbers of patients in each group. Sample size calculations
were conducted using PS (Version 3.0, 2009, Vanderbilt
University, Nashville, TN, USA).
The primary end point of the study wasa composite variable
ofIBD-relatedhospitalizationorsurgeryinthefollow-upperiod.
Continuous variables that were normally distributed were
expressed as mean±s.d., whereas non-normally distributed
continuous variables were expressed as median (range).
Event-free survival probabilities were estimated by the
Kaplan–Meier method and the comparison between patients
with normal and elevated gap densities was conducted via the
log-ranktest.TheCoxproportionalhazardsmodelwasusedto
assess gap density as a continuous predictor for the risk of
major clinical events. Two-sided P values of o0.05 were
considered to be signiﬁcant. For secondary analysis, we
assessed the relationship between epithelial gap density
and other outcomes of interest using appropriate non-
parametric tests. The relationship between epithelial gap
density and ordinal outcomes (years since diagnosis,
number of ﬂares, disease severity, and CRP levels at the
timeofcolonoscopy) wereassessedwiththe Spearmanrank
correlation coefﬁcient. When assessing the relationship
between gap density and binary outcomes (gender, need
forTNFagents),theWilcoxonranksumtestwasused.When
assessing the relationship between gap density and nominal
outcomes (disease location), the Kruskal–Wallis test was
used. All analyses were conducted using the STATA data
analysis and statistical software (StataCorp LP, College
Station, TX).
RESULTS
Baseline study patient characteristics. The baseline study
patient characteristics are shown in Table 1. There were 41
IBD patients (21 CD and 20 UC) in the study with a median
follow-up of 14 (5–31) months. Study patients included those
from our pilot study (7 CD and 1 UC) and 26 patients from our
prospective IBD gap density study who remained in Alberta for
the follow-up period (14 CD and 12 UC), and an additional 7
UC patients. Indications for colonoscopy in the 41 patients
were: evaluation of symptoms in 27 (15 CD and 12 UC) and
cancer surveillance in 14 (6 CD and 8 UC). The age, gender,
disease duration, and serum CRP levels were comparable
between CD and UC patients. The median follow-up period for
CD patients was longer than that for UC patients (14 vs. 18.5
months, P¼0.01). Follow-up data were available for all study
patients. Multiple hospitalizations or surgeries in the same
patient were counted as one event for the primary outcome
analysis, and the time to ﬁrst event was used for analysis. The
median follow-up for patients with elevated gap density was
longer than that for patients with normal gap density (13 vs. 17
months, P¼0.02).
Correlation of epithelial gap density and rate of
hospitalization or surgery. Patients with normal gap
density were found to be at lower risk for events
(hospitalization or surgery) than those with elevated gap
density (P¼0.02 from log-rank test) during the follow-up
period, shown in Figure 1. Using Cox proportional hazards
analysis, gap density was found to be a signiﬁcant predictor
for risk of events, with a hazard ratio of 1.10 (95% conﬁdence





Age (years), mean±s.d. 37.2±14.5 45.0±15.5
% Male 48 55
Disease duration (years),
median (IQR)
6 (0–17) 3 (0.75–11)





Left side/proctitis 8 (40)
Endoscopic disease severity (%)
Normal 2 (10) 4 (20)
Mild 11 (52) 11 (55)
Moderate 5 (24) 5 (25)
Severe 3 (14)
Medications (%)
No therapy 8 (38) 6 (30)
Aminosalicylate 4 (19) 11 (55)
Steroids 2 (10) 3 (15)
Immunomodulator 6 (29) 4 (20)
Biologics 3 (14) 0 (0)
C-reactive protein, median
(IQR)
5.5 (1.8, 14.2) 2.9 (2.3–15.4)
IQR, interquartile range.
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gap density, shown in Figure 2. Whether the patient had
active or inactive disease at the time of colonoscopy was not
predictive of the need for hospitalization or surgery in follow-
up. In all, 3 of the 14 (21%) IBD patients undergoing
surveillance colonoscopy had a major event, whereas 4 of
27 (15%) patients undergoing colonoscopy for symptomatic
evaluation had a major event in the follow-up period.
Correlation of epithelial gap density and IBD ﬂares. In
the 34 remaining patients who did not have a major clinical
event in the follow-up period, 10 had symptomatic ﬂares
(29%). Epithelial gap density was marginally correlated with
the number of ﬂares in the follow-up period, with a Spearman
rank correlation coefﬁcient (r) of 0.27 (P¼0.08). Flares were
successfully managed by gastroenterologists in an outpatient
setting. Two patients were treated with dose escalation of
existing medical therapy, whereas others required step-up
therapy to immunomodulators or anti-TNF therapy. There
was no correlation between anti-TNF therapy initiation and
epithelial gap density (P¼0.28).
Correlation of epithelial gap density and other clinical
parameters. We examined the relationship between
epithelial gap density and the following clinical parameters:
duration of IBD, endoscopic disease severity and location,
CRP level at the time of colonoscopy, and gender. We found
a signiﬁcant positive correlation between epithelial gap
density and the duration of IBD (years since diagnosis),
with a r of 0.44 (P¼0.004), shown in Figure 3. Male IBD
patients also appeared to have a higher median epithelial
gap density compared with female IBD patients: 9.0 vs. 3.6
gaps per 100 cells counted (P¼0.038), shown in Figure 4.
No signiﬁcant relationships were found with endoscopic
disease severity or location, and CRP levels.






































Figure 2 Hazard ratio associated with epithelial gap density as a continuous
predictor from the Cox proportional hazards model (P¼0.034).
Figure 3 Distribution of intestinal epithelial gap densities as a function of
disease duration for inﬂammatory bowel disease (IBD) patients. Epithelial gap
density is expressed as the number of epithelial gaps per 100 cells counted.
P¼0.004.
Figure 1 Kaplan–Meier plot of event-free survival probabilities in inﬂammatory
bowel disease (IBD) patients with normal and elevated gap densities following
probe-based confocal laser endomicroscopy.
Figure 4 Comparison of epithelial gap density of the small intestine for male
and female inﬂammatory bowel disease (IBD) patients. *P¼0.038.
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In this study, we found that the density of epithelial gaps in the
terminal ileum of IBD patients as determined by pCLE was
predictive of the need for hospitalization or surgery during
follow-up. This ﬁnding supports our hypothesis that excess
epithelial cell extrusion in IBD (measured as an increased
epithelial gap density) serves as a surrogate marker for
mucosal barrier dysfunction, thus having a prognostic value
for clinical course of disease. Consistent with a recent report
that barrier dysfunction from cell extrusion is predictive of
disease relapse,
19 our results indicate that gap density, a
semi-quantitative measure of cell extrusion, is a linear
predictor for future major events such as hospitalization or
surgery in IBD.
Endoscopic ﬁndings associated with aggressive IBD
include deep and extensive ulcerations and lack of mucosal
healing,
36 particularly after administration of anti-TNF ther-
apy.
34,35 Based on experience from the past few years, some
ofthenew therapeutic goalsforIBD treatment are steroid-free
remission, mucosal healing, and reduction in hospitalization
and surgery.
37 Hospital admission and surgery is associated
with increased morbidity and mortality for patients, and
signiﬁcant costs.
38 Therefore, delineation of the predictors
for IBD patients at high risk for major events during their
colonoscopy would be valuable. Recently, local barrier
dysfunction identiﬁed by the Watson grade of cell shedding
and the presence of ﬂuorescein leakage and micro-erosions
on CLE was shown to be predictive of relapse in IBD.
19
Consistent with their ﬁndings, our study results indicate that
the epithelial gap density, a semi-quantitative measure of
barrierdisruptionintheepitheliallining,canidentifypatientsat
risk for a more severe disease course, that is, the need for
IBD-related hospitalization or surgery.
The positive correlation observed between epithelial gap
density and disease duration in IBD indicates that excess
epithelial cell extrusion, either as a cause or as a result of the
diseaseprocess,appearstobeincreasedwithlongerduration
of disease. This is consistent with the observation that young
age at diagnosis is associated with more aggressive disease
for both CD and UC patients. Interestingly, the endoscopic
location of disease did not correlate with gap density in
Crohn’s patients, that is, patients with ileitis did not have
elevated gap density in normal-appearing areas of the
terminal ileum. Epithelial gap density in the terminal ileum
appeared not to be inﬂuenced by the presence of disease in
the immediate surrounding areas. Epithelial gap density also
did not correlate with systemic CRP levels, suggesting that
epithelial cell extrusion is mediated by events at the mucosal
level rather than by systemic inﬂammation.
We found a marginal correlation between epithelial gap
density and the number of relapses in the follow-up period. In
addition,thegapdensitycorrelatedwiththedurationofdisease
in IBD patients, supporting a potential role of epithelial barrier
dysfunctioninthepathogenesisofIBD.Inthecurrentstudy,we
did not ﬁnd a relationship between epithelial gap density and
endoscopic severity or location of disease. We did ﬁnd that
male IBD patients appeared to have higher gap densities than
female patients. In a recent study, male gender was identiﬁed
as an independent risk factor for the development of complica-
tions in CD,
24 whereas other studies suggest that women
appearedtobeathigherriskforintestinalresectionandsurgery
in CD.
20,23,39 Future large, prospective studies are needed to
clarify the effect of gender on clinical outcomes.
IBD is a chronic disease and most patients will experience
ﬂares. A recent prospective longitudinal study conducted in
Norway reported a cumulative relapse rate of 90% in CD
patients.
20 It is important to be able to identify a subgroup of
patients at risk for serious ﬂares requiring hospitalization or
surgical management. Although our study results are pre-
liminary, it appears that a higher gap density is predictive of
more severe clinical disease. A higher gap density may reﬂect
increased epithelial cell shedding induced by enhanced
TNF-aand otherproinﬂammatorycytokineactivities.Itremains
to be determined how this impacts disease management.
There are several limitations to our current study. This is a
relatively small study of 41 patients, and our results will need
tobeconﬁrmedinlarger,multi-centeredstudiesofgapdensity
determination in IBD patients. The follow-up period is longer
for CD compared with UC, as many UC patients were
recruited at a later time, despite the difference in follow-up
time, we still found a signiﬁcant relationship between elevated
gap density and major clinical events using a log-rank test,
stratiﬁed by disease status. Although we observed a marginal
relationship between epithelial gap density and the number of
ﬂares in the follow-up period, our study was not designed to
evaluate this end point, and may be underpowered to
ascertain a signiﬁcant relationship.
In conclusion, we show that the epithelial gap density in the
terminal ileum, asdetermined by pCLEduring colonoscopy, is
a predictor for aggressive clinical disease in IBD. CLE
evaluation of the terminal ileum during colonoscopy may
enable clinicians to further risk stratify IBD patients.
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cells can be visualized in the small intestine in
patients using confocal laser endomicroscopy.
| The density of the epithelial gaps in inﬂammatory
bowel disease patients is creased compared to
non-IBD controls.
WHAT IS NEW HERE
| In IBD patients, increased epithelial gap density is
an endoscopic predictor of aggressive disease.
| Epithelial gap density is correlated with duration of
IBD disease, and marginally related to the number
of ﬂares in follow up.
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